Desferrioxamine p benzyl isothiocyanate dfo bz ncs

The production of [⁸⁹Zr]oxalate was carried out the University of Alabama at Birmingham, Cyclotron Facility using Y sputtered solid targets as described previously^{43 (link)}. Panitumumab (Vectibix®) was purchased from Amgen (Thousand Oaks, CA). Desferrioxamine-p-benzyl-isothiocyanate (DFO-Bz-NCS) was purchased from Macrocyclics (Dallas, TX). Dimethyl sulfoxide (DMSO) and sodium carbonate were purchased from Sigma-Aldrich (St. Louis, MO). HEPES was purchased from ACROS Organic (Fair Lawn, NJ). All other chemicals were purchased from Fisher Scientific (Hampton, NH) unless stated otherwise.

All reagents were of analytical grade and used without further purification unless otherwise stated. Chelex-100 resin was purchased from Bio-Rad Laboratories (Richmond, CA) and used with aqueous buffers for radiolabeling experiments to ensure metal-free conditions. Trastuzumab and pertuzumab were obtained from Genentech (San Francisco, CA). Control IgG1 antibodies, 88R20 and mAb-69 were kindly provided by Dr. Kendra Carmon and Dr. Barret R. Harvey, the University of Texas Health Science Center at Houston. IRDye800CW-NHS was purchased from LI-COR Biosciences (Lincoln, NE). Desferrioxamine-p-benzyl-isothiocyanate (DFO-Bz-NCS) was purchased from Macrocyclics (Plano, TX). Zirconium-89 (⁸⁹Zr)-oxalate was produced by Washington University School of Medicine (St. Louis, MO). Size-exclusion high-performance liquid chromatography (SEC-HPLC) was performed on an analytical Hitachi LaChrom system using a TSKgel G3000SW (5 μm) column and mobile phases of A = 0.1 M sodium phosphate buffer (pH 7.3) and B = CH₃CN (isocratic: 90% A and 10% B) and a flow rate of 1 mL/min. Radiochemical yield and purity were measured with a radio-thin-layer chromatography (TLC)/HPLC detector system (LabLogic) using previously described methods [15 (link)].

[⁸⁹Zr]oxalate was produced at the Cyclotron Facility at the University of Alabama at Birmingham (UAB) from the ⁸⁹Y(p,n)⁸⁹Zr reaction using ⁸⁹Y sputtered targets as described previously [22 (link)]. Atezolizumab (Tecentriq^®) was purchased from Genentech (San Francisco, CA, USA). Desferrioxamine-p-benzyl-isothiocyanate (DFO-Bz-NCS) was purchased from Macrocyclics (Dallas, TX, USA). All other chemicals were purchased from Fisher Scientific (Hampton, NH, USA) except where otherwise stated.